These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. Wikstrand CJ; Reist CJ; Archer GE; Zalutsky MR; Bigner DD J Neurovirol; 1998 Apr; 4(2):148-58. PubMed ID: 9584952 [TBL] [Abstract][Full Text] [Related]
4. Targeting epidermal growth factor receptor variant III: a novel strategy for the therapy of malignant glioma. Sonabend AM; Dana K; Lesniak MS Expert Rev Anticancer Ther; 2007 Dec; 7(12 Suppl):S45-50. PubMed ID: 18076318 [TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for glioma: getting closer to the clinical arena? Finocchiaro G; Pellegatta S Curr Opin Neurol; 2011 Dec; 24(6):641-7. PubMed ID: 22027543 [TBL] [Abstract][Full Text] [Related]
6. Passive antibody-mediated immunotherapy for the treatment of malignant gliomas. Mitra S; Li G; Harsh GR Neurosurg Clin N Am; 2010 Jan; 21(1):67-76. PubMed ID: 19944967 [TBL] [Abstract][Full Text] [Related]
7. [Novel immunotherapeutic approach]. Kikuchi T Gan To Kagaku Ryoho; 2005 Apr; 32(4):453-7. PubMed ID: 15853209 [TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of human glioma xenografts with unlabeled, 131I-, or 125I-labeled monoclonal antibody 425 to epidermal growth factor receptor. Bender H; Takahashi H; Adachi K; Belser P; Liang SH; Prewett M; Schrappe M; Sutter A; Rodeck U; Herlyn D Cancer Res; 1992 Jan; 52(1):121-6. PubMed ID: 1727372 [TBL] [Abstract][Full Text] [Related]
9. Novel mechanisms and approaches in immunotherapy for brain tumors. Finocchiaro G; Pellegatta S Discov Med; 2015; 20(108):7-15. PubMed ID: 26321082 [TBL] [Abstract][Full Text] [Related]
10. Cell- and peptide-based immunotherapeutic approaches for glioma. Yamanaka R Trends Mol Med; 2008 May; 14(5):228-35. PubMed ID: 18403264 [TBL] [Abstract][Full Text] [Related]
11. Tumor immunology: a neurosurgical perspective. II. The immunology of glial neoplasms. Apuzzo ML Bull Los Angeles Neurol Soc; 1976 Oct; 41(4):176-83. PubMed ID: 74264 [TBL] [Abstract][Full Text] [Related]
13. EGF receptor variant III as a target antigen for tumor immunotherapy. Li G; Wong AJ Expert Rev Vaccines; 2008 Sep; 7(7):977-85. PubMed ID: 18767947 [TBL] [Abstract][Full Text] [Related]